G protein–coupled receptors (GPCRs) respond to a chemically diverse plethora of signal
transduction molecules. The notion that GPCRs also signal without an external chemical …

Pharmacogenetics investigates the influence of genetic variants on physiological
phenotypes related to drug response and disease, while pharmacogenomics takes a …

By virtue of their large number, widespread distribution and important roles in cell
physiology and biochemistry, G-protein-coupled receptors (GPCR) play multiple important …

Numerous genes encode G protein-coupled receptors (GPCRs)-a main molecular target for
drug therapy. Estimates indicate that the human genome contains approximately 600 GPCR …

G protein-coupled receptors (GPCRs) represent a major class of proteins in the genome of
many species, including humans. In addition to the mapping of a number of human …

G protein-coupled receptors (GPCRs) are known to interact with several other classes of
integral membrane proteins that modulate their biology and pharmacology. However, the …

The existence of constitutive activity for G protein-coupled receptors (GPCRs) was first
described in 1980s. In 1991, the first naturally occurring constitutively active mutations in …

During the past few years, crystallography of G protein–coupled receptors (GPCRs) has
experienced exponential growth, resulting in the determination of the structures of 16 distinct …

The complete sequencing of the human genome has afforded researchers the opportunity to
identify novel G-protein-coupled receptors (GPCRs) that are expressed in human tissues …

Modulators of G protein-coupled receptors (GPCRs) form a key area for the pharmaceutical
industry, representing˜ 27% of all Food and Drug Administration (FDA)-approved drugs …